Essential Partners’s Edgewise Therapeutics EWTX Stock Holding History

Essential Partners’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.42K	Buy	35 +32	+1,067%	+$1.36K	﹤0.01%	2050
2026 Q2	$122	Hold	3	–	–	﹤0.01%	2723
2026 Q1	$95	Hold	3	–	–	﹤0.01%	2722
2025 Q4	$74	Buy	+3	New	+$60	﹤0.01%	2593

Other funds holding EWTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GIA

GHP Investment Advisors Denver, Colorado $2.68B AUM 19.3% 1-Year Est. Return

Essential Partners's EWTX Position: Q3 2026 in Review

Essential Partners increased its Edgewise Therapeutics (EWTX) stake by 1,067% in Q3 2026, buying an estimated $1.36K and bringing the position to 35 shares worth $1.42K. The position accounts for ﹤0.01% of the portfolio, ranked #2050.

Essential Partners first reported a position in EWTX in Q4 2025 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold EWTX as of Q3 2026.

Essential Partners held 35 shares of Edgewise Therapeutics worth $1.42K as of Q3 2026.
Essential Partners bought 32 Edgewise Therapeutics shares in Q3 2026, an estimated $1.36K.
Edgewise Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2050 holding.
Essential Partners first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 4 quarters since.
9 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.